KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Work In Process (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Work In Process for 15 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process rose 52.68% to $30.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.9 million, a 52.68% increase, with the full-year FY2025 number at $30.9 million, up 52.68% from a year prior.
  • Work In Process was $30.9 million for Q4 2025 at Halozyme Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $56.2 million in Q3 2022 to a low of $600000.0 in Q1 2025.
  • A 5-year average of $23.1 million and a median of $20.6 million in 2021 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: soared 332.75% in 2023, then plummeted 96.46% in 2025.
  • Halozyme Therapeutics' Work In Process stood at $17.5 million in 2021, then soared by 152.72% to $44.1 million in 2022, then fell by 22.85% to $34.0 million in 2023, then plummeted by 40.48% to $20.3 million in 2024, then skyrocketed by 52.68% to $30.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Work In Process are $30.9 million (Q4 2025), $2.5 million (Q3 2025), and $1.3 million (Q2 2025).